HEMAB THERAPEUTICS HOLDINGS INC (COAG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$44.41+0.09%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · COAG
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue clinical trials and regulatory progress for sutacimig as a prophylactic treatment for Glanzmann thrombasthenia and Factor VII deficiency.
Newly stated in 2026-Q2. Management announced FDA endorsement of sutacimig clinical data to proceed to Phase 3 pivotal trial in GT, with initiation planned in second half of 2026. No prior quarters in the bundle mention this, so this is a new strategic development priority with clear regulatory progress.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Not enough signal yet.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“FDA has endorsed the Company’s clinical data package as sufficient to proceed to a Phase 3 pivotal trial in GT with a dose of 0.2 mg/kg once weekly.”
Advance clinical trials of HMB-002 as a novel subcutaneous prophylactic treatment for Von Willebrand Disease with promising early clinical data.
Newly stated in 2026-Q2. Management presented first-in-human data showing a ≥2.4-fold increase in VWF and FVIII for HMB-002 in VWD patients, indicating proof of mechanism. This is an early clinical development priority with promising initial results but no prior quarters to compare.
“Data from the ongoing VELORA Pioneer Phase 1/2 trial demonstrated proof of mechanism, a ≥2.4-fold peak increase in VWF and FVIII.”
Initiate first-in-human studies for HMB-003, a novel peptide plasmin inhibitor for heavy menstrual bleeding and other bleeding conditions.
Newly stated in 2026-Q2. Management announced the launch of HMB-003 program with plans to start first-in-human studies in second half of 2026. This is a new strategic initiative with preclinical data supporting its potential, with no prior quarters mentioning it.
“The Company plans to initiate first-in-human studies in the second half of 2026 with initial clinical data mid-2027.”
Manage cash and capital resources to fund operating expenses and capital expenditures through 2029.
Newly stated in 2026-Q2. Management reported cash and equivalents of $457.5 million as of June 30, 2026, following a $317.2 million IPO net proceeds, supporting a cash runway into 2029. This is a continuing operational priority with clear financial backing but only one quarter of data.
“The Company believes its current cash, cash equivalents, and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into 2029.”
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.